Log In
BCIQ
Print this Print this
 

AL-8176

Also known as: ALS-8176

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionOral respiratory syncytial virus (RSV) nucleoside analog
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationRespiratory syncytial virus (RSV)
Indication DetailsTreat respiratory syncytial virus (RSV) infection
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,750.0M

$1,750.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

11/07/2014

$1,750.0M

$1,750.0M

0

Get a free BioCentury trial today